The American Journal of Managed Care

Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

Allison Wheeler, MD, explores the transformative journey of hemophilia A treatment, from blood products to advanced recombinant factor therapies, longer half-life products, and subcutaneous injections ...
Monthly Prescribing Reference

ISTH Issues Clinical Practice Guideline for the Treatment of Hemophilia

Prophylaxis recommended over episodic treatment of bleeding events for severe and moderately severe hemophilia A and B. HealthDay News — In a clinical practice guideline issued by the International ...
WKRG

ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment

CHAPEL HILL, N.C., June 21, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), the leading international professional medical-scientific organization dedicated to ...
Medscape

New Approaches to Hemophilia Treatment: 'Our Cup Runneth Over'

ATLANTA, Georgia — It's a problem many clinicians would love to have: a whole variety of new or emerging therapeutic options to use in the care of their patients. In a session titled "Hemophilia ...

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...
Business Insider

World Federation of Hemophilia (WFH) publishes "The WFH Guidelines for the Management of Hemophilia, 3rd edition"

Hemophilia Guidelines for All: A new ambition of the World Federation of Hemophilia (WFH) MONTREAL, Aug. 4, 2020 /PRNewswire/ - Led by content leads, Alok Srivastava, MD, and Glenn Pierce, MD, PhD, ...
Badgers Wire

Michigan man gets new Roctavian gene therapy for hemophilia A

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene therapy for severe hemophilia A.
Seeking Alpha

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, ...
Nasdaq

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in ...
Business Wire

New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced ...
Healthline

Complications of Hemophilia and How to Prevent Them

Hemophilia may lead to internal bleeding, particularly in joints and the brain, which could cause pain, swelling, and neurological symptoms. Preventive treatment with clotting factor concentrates and ...
The American Journal of Managed Care

Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study

This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization ...